334 related articles for article (PubMed ID: 33514507)
1. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.
Yoon D; Lee JH; Lee H; Shin JY
BMJ; 2021 Jan; 372():m4931. PubMed ID: 33514507
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Scheller NM; Svanström H; Pasternak B; Arnheim-Dahlström L; Sundström K; Fink K; Hviid A
JAMA; 2015 Jan; 313(1):54-61. PubMed ID: 25562266
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.
Arnheim-Dahlström L; Pasternak B; Svanström H; Sparén P; Hviid A
BMJ; 2013 Oct; 347():f5906. PubMed ID: 24108159
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.
Hviid A; Svanström H; Scheller NM; Grönlund O; Pasternak B; Arnheim-Dahlström L
J Intern Med; 2018 Feb; 283(2):154-165. PubMed ID: 29044769
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
Eun BW; Bahar E; Xavier S; Kim H; Borys D
Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
[TBL] [Abstract][Full Text] [Related]
6. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
[TBL] [Abstract][Full Text] [Related]
7. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
8. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
[TBL] [Abstract][Full Text] [Related]
10. Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort.
Hviid A; Myrup Thiesson E
JAMA Netw Open; 2021 Aug; 4(8):e2120391. PubMed ID: 34436612
[TBL] [Abstract][Full Text] [Related]
11. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
[TBL] [Abstract][Full Text] [Related]
12. Adverse events from HPV vaccination in Taiwan.
Tsai SA; Lu CY; Chen TI; Huang SP; Chen YC
Vaccine; 2023 Nov; 41(49):7444-7449. PubMed ID: 37949754
[TBL] [Abstract][Full Text] [Related]
13. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous preterm birth risk among HPV-vaccinated and -unvaccinated women: a nationwide retrospective cohort study of over 240 000 singleton births.
McClymont E; Faber MT; Belmonte F; Kjaer SK
BJOG; 2023 Mar; 130(4):358-365. PubMed ID: 36424904
[TBL] [Abstract][Full Text] [Related]
15. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer.
Kjaer SK; Dehlendorff C; Belmonte F; Baandrup L
J Natl Cancer Inst; 2021 Oct; 113(10):1329-1335. PubMed ID: 33876216
[TBL] [Abstract][Full Text] [Related]
17. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
[TBL] [Abstract][Full Text] [Related]
18. Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis.
Krogsgaard LW; Petersen I; Plana-Ripoll O; Bech BH; Lützen TH; Thomsen RW; Rytter D
PLoS Med; 2021 Sep; 18(9):e1003768. PubMed ID: 34495975
[TBL] [Abstract][Full Text] [Related]
19. Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands.
Schurink-Van't Klooster TM; de Ridder MA; Kemmeren JM; van der Lei J; Dekker F; Sturkenboom M; de Melker HE
Eur J Pediatr; 2015 May; 174(5):641-9. PubMed ID: 25367054
[TBL] [Abstract][Full Text] [Related]
20. No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls.
Schurink-Van't Klooster TM; Kemmeren JM; van der Maas NAT; van de Putte EM; Ter Wolbeek M; Nijhof SL; Vanrolleghem AM; van Vliet JA; Sturkenboom M; de Melker HE
Vaccine; 2018 Oct; 36(45):6796-6802. PubMed ID: 30262246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
